Showing results (371-380 of 483) with videos related to
Sort By:
Pageof 49
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.Oncotarget|February 5, 2017
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigensLinus Backert, Daniel Johannes Kowalewski, Simon Walz, et al.NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.Frontiers in Oncology|November 17, 2022
Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinomaLinus D Kloker, Branko Calukovic, Katrin Benzler, et al.The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.European Journal of Cancer (Oxford, England : 1990)|May 18, 2016
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantationMaximilian Merz, Lina Jansen, Felipe A Castro, et al.Pageof 49